ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis — Recruiting • Phase III • Rheumatology • NCT06807424.
- New drug icotrokinra tested against placebo for psoriatic arthritis in patients with and without previous biologic treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA. Conditions: Arthritis, Psoriatic Interventions: Icotrokinra, Placebo Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 750 participants